Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)

Business Wire May 17, 2017

Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes

Business Wire May 6, 2017

Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

Benzinga.com  May 5, 2017

Celgene Corporation to Webcast at Upcoming Investor Conferences

Business Wire May 3, 2017

Biotech Stocks on Investors' Radar -- Array BioPharma, Celgene, Amgen, and Cerulean Pharma

PR Newswire May 3, 2017

Celgene Reports First Quarter 2017 Operating and Financial Results

Business Wire April 27, 2017

Earnings Scheduled For April 27, 2017

Benzinga.com  April 27, 2017

9 Leveraged ETFs That Could Be Hot This Week

Benzinga.com  April 25, 2017

Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies

PR Newswire April 6, 2017

Celgene Notified of ANDA Filing for POMALYST®

Business Wire April 3, 2017

Celgene Corporation to Announce First Quarter 2017 Results on April 27, 2017

Business Wire April 3, 2017

Biotech Stocks Under Scanner -- MannKind, Opko Health, Celgene, and Array BioPharma

PR Newswire March 20, 2017

5 Biotech Companies Set for Major Breakouts in 2017

PR Newswire March 17, 2017

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Business Wire March 5, 2017

Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

Business Wire March 3, 2017

FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

Business Wire March 1, 2017

Celgene Corporation to Webcast at Upcoming Investor Conferences

Business Wire February 27, 2017

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation

Business Wire February 24, 2017

Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer

Business Wire February 23, 2017

FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Business Wire February 22, 2017